Soriot was tasked with turning around a troubled AstraZeneca - hit by a string of key patent losses and a spate of clinical trial failures - in October 2012, following a stint at pharma peer Roche. With the Frenchman at the helm, the fortunes of the Anglo-Swedish drugmaker changed dramatically.